Lenalidomide and the Expanding Toolkit to Manage Kaposi Sarcoma

David H Henry; Robert G Maki

doi:10.1158/1078-0432.CCR-22-0884

Lenalidomide and the Expanding Toolkit to Manage Kaposi Sarcoma

Clin Cancer Res. 2022 Jun 13;28(12):2485-2487. doi: 10.1158/1078-0432.CCR-22-0884.

Authors

David H Henry¹, Robert G Maki^{1

2}

Affiliations

¹ Pennsylvania Hospital, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
² Hospital of the University of Pennsylvania, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

PMID: 35380669
DOI: 10.1158/1078-0432.CCR-22-0884

Abstract

Lenalidomide recently was shown to have clinical activity in patients with human immunodeficiency virus-associated Kaposi sarcoma. Immunomodulatory imine drugs thus provide another tool in the treatment of this challenging neoplasm. See related article by Reid et al., p. 2646.

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

HIV Infections* / complications
HIV Infections* / drug therapy
Humans
Lenalidomide / therapeutic use
Sarcoma, Kaposi* / diagnosis
Sarcoma, Kaposi* / drug therapy

Substances

Lenalidomide